In addition to multiple studies focusing on anti-PD1/PD-L1 and anti-CTLA4 antibodies, other immune co-inhibitory and co-stimulatory agents are being actively studied to enhance the efficacy of cancer vaccines. Here, CTLA4 is linked to cancer.